Sign In
Buy CRBU
$2.00
-0.320 (-13.79%)
At Close: Jun 03, 2026
7 Cheap Biotech Stocks to Buy Now
04:42pm, Wednesday, 03'rd Aug 2022
Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.
Morphic Holding, Inc. (MORF) Surpasses Q2 Earnings and Revenue Estimates
01:25pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 183.95% and 1,317.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stoc
Incyte (INCY) Q2 Earnings and Revenues Surpass Estimates
12:25pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Incyte (INCY) delivered earnings and revenue surprises of 27.85% and 11.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Caribou Biosciences: Potential To Change CAR-T Landscape
02:19pm, Monday, 01'st Aug 2022
Proof of concept established using CRISPR allogeneic CAR-T CB-010 for the treatment of patients with relapsed/refractory B-cell Lymphoma. Additional results from the phase 1 ANTLER study using CB-010
Legend Biotech Corporation Sponsored ADR (LEGN) Soars 10.9%: Is Further Upside Left in the Stock?
12:30pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Legend Biotech Corporation Sponsored ADR (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue mo
What's Going On With Caribou Biosciences Shares Today?
01:23pm, Friday, 10'th Jun 2022
Caribou Biosciences, Inc. (NASDAQ: CRBU) shares are trading lower after the company reported additional data from its CB-010 allogeneic CAR-T cell therapy Phase 1 ANTLER trial at the European Hematol
Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress
07:00am, Friday, 10'th Jun 2022 GlobeNewswire Inc.
-- 100% CR rate (6 of 6 patients), with 40% CR rate (2 of 5 patients) at 6 months, achieved as best response following 1 dose at the initial dose level in patients with aggressive r/r B-NHL -- -- Firs
Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022
08:05pm, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
-- Poster presentation at the European Hematology Association (EHA) 2022 Congress to take place on Friday, June 10 and include additional data from dose level 1 patients -- -- Poster presentation at t
Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022
04:05pm, Wednesday, 01'st Jun 2022
-- Poster presentation at the European Hematology Association (EHA) 2022 Congress to take place on Friday, June 10 and include additional data from dose level 1 patients -- -- Poster presentation at t
Caribou CEO discusses his company's unicorn status, its plans going forward, and its culture
05:29pm, Thursday, 19'th May 2022
Caribou CEO Kevin Bennett sits down with Yahoo Finance Live to discuss his company's business outlook after receiving funding, car price trends, and refinancing cars.
The Correction In Biopharmaceutical Stocks Is Likely Over
04:51am, Wednesday, 18'th May 2022 Seeking Alpha
Biopharmaceutical stocks have undergone a dramatic correction over the past six months, with the XBI declining by 45%. I highlight stocks that are attractively priced.
Caribou Charges Ahead on Study Results
03:07pm, Tuesday, 17'th May 2022
Shares of Caribou Biosciences Inc. ( CRBU , Financial) are up more than 46% since last Thursday, leading the way for several beaten-down biotechs that also rose after investors got a look at the prese
4 Analysts Have This to Say About Caribou Biosciences
09:03pm, Tuesday, 10'th May 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on Caribou Biosciences (NASDAQ:CRBU) stock. These analysts are typically employed by large Wall Street banks and tasked with understandi
Caribou Biosciences to Present at Upcoming Investor Conference
08:05pm, Tuesday, 03'rd May 2022 GlobeNewswire Inc.
BERKELEY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Hau
Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress
08:05pm, Monday, 25'th Apr 2022 GlobeNewswire Inc.
-- Abstract accepted on initial clinical data from the ANTLER Phase 1 trial of CB-010, Caribou’s lead allogeneic cell therapy for patients with r/r B-NHL -- -- Abstract accepted on initial clinical
